Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS8179 for prevention and treatment of severe cerebral edema after large hemispheric infarction
CTR20244719Phase 3Active
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS8179 in ischemic stroke, cerebral edema, sponsored by Beijing Shengdi Pharmaceutical. Started Feb 2025; status: active.
02
Drugs
HRS8179
03
Conditions
ischemic strokecerebral edema
Beyond the preview
Go deeper on CTR20244719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244719.